Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C

Drug interactions with new hepatitis C oral drugs

(2015) Vincent Soriano et al.   Expert Opinion on Drug Metabolism & Toxicology

Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials

(2015) Zobair M. Younossi et al.   HEPATOLOGY

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

(2015) Anu Osinusi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

(2015) Marc Bourlière et al.   LANCET INFECTIOUS DISEASES

Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse

(2014) Anu Osinusi et al.   ANNALS OF INTERNAL MEDICINE

Sofosbuvir

(2014) Lucia Rose et al.   ANNALS OF PHARMACOTHERAPY

The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C

(2014) Zobair Younossi et al.   DIGESTIVE AND LIVER DISEASE

Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors

(2014) Makonen Belema et al.   JOURNAL OF MEDICINAL CHEMISTRY

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

(2014) Eric Lawitz et al.   LANCET

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C Virus Testing of Persons Born During 1945–1965: Recommendations From the Centers for Disease Control and Prevention

(2013) Bryce D. Smith et al.   ANNALS OF INTERNAL MEDICINE

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

(2013) David Alan Herbst et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies

(2013) Jianmeng Chen et al.   GASTROENTEROLOGY

NS5A inhibitors in the treatment of hepatitis C

(2013) Jean-Michel Pawlotsky   JOURNAL OF HEPATOLOGY

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

(2013) John O. Link et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

(2012) Patrick Marcellin et al.   Expert Opinion On Drug Safety

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

(2012) Eric J. Lawitz et al.   JOURNAL OF HEPATOLOGY

Treatment of chronic hepatitis C - are interferons really necessary?

(2011) Peter Ferenci   LIVER INTERNATIONAL

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C

(2008) J. McHutchison et al.   JOURNAL OF VIRAL HEPATITIS